The NHS is rolling out its first virtual hospital, using the NHS App to connect patients with specialists, AI-powered triage, and faster access to tests.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
Childhood air pollution has been understood as partially responsible for respiratory health - now, researchers are investigating at how exposure can damage cognitive ability later on in life.
According to data collected by 400 healthcare professionals at the worst moment of the US outbreak, the life support machine that acts in place of the heart and lungs is crucial to reducing COVID-19 deaths for the critically ill.
An STFC-funded project, MoleGazer, has successfully implemented astronomical techniques, used for star-gazing, to detect and track the evolution of cancerous moles.
A professor describes severe maternal morbidity in low-income women as a public health crisis - now, Medicaid expansion seems to be improving pregnancy outcomes.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
Hugh Bettesworth, CEO, Mirada Medical, explores how AI autocontouring technology can help tackle the cancer care backlog as a result of the COVID-19 pandemic.
New data from the REACT study finds that the rising infection rate has steadied a little, but there is no "sharp drop in infections" as in the first wave and the R is still high.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
Professor Herb Sewell, expert in immunology, wrote that the UK Government should not rely on one dose of the vaccine - suggesting that the diluted vaccine could encourage mutations to evolve.
New data from the REACT study says that there have been more than 20 hospitals' worth of new patients since Christmas Eve, putting "extreme pressure" on the NHS.
